Innovative drug development in China is entering a phase of unprecedented dynamism. A trend powerfully illustrated by a 59% surge in approvals during the first half of 2025. This accelerated pace is fundamentally reshaping the…
Bolstered by dual drivers of policy support and capital influx, China’s innovative drug industry is rapidly advancing towards a golden era of high-quality development. Innovative Drug Policy Support: Faster Clinical Trial Approval and Improved Payment…
The Prescription Drug User Fee Act (PDUFA) date marks the deadline by which the U.S. Food and Drug Administration (FDA) must complete its review of a New Drug Application (NDA) or Biologics License Application (BLA).…
Thyroid cancer is now the focus of a newly established national awareness day in China, as “Thyroid Cancer Prevention and Treatment Day.” Jointly initiated by leading major professional medical associations in China, this move is…
DengYueMed reports the latest developments in global new drug approvals and submissions for early September 2025. Newly Approved Drugs 1. Lecanemab Subcutaneous Auto-Injector (IQLIK™) 2. Inebilizumab Injection (XinYue®) 3. Denosumab Injection (HLX14) 4. Teplizumab Injection…
Source: Dengyuemed | September 27, 2025 | Category: Pharmaceuticals As a Hong Kong drug wholesale distributor, we closely follow China Medical’s progress across innovative drug development, biosimilars, and global expansion. By tracking these breakthroughs —…
In 2024, the U.S. FDA approved more than 60 innovative therapies and vaccines, highlighting a record year for medical progress. Looking ahead, based on the Prescription Drug User Fee Act (PDUFA) timelines, the FDA is…
HKDengyuemed stated, “In cancer care, achieving five-year survival is a critical milestone, often synonymous with long-term remission.” Marking the fifth anniversary of its “China 2030 Strategy,” Bristol-Myers Squibb (BMS) reflects on a period of significant…
Introduction: This milestone marks another solid step forward for China in the field of innovative drug development for hepatitis B. Hepatitis B, as a global public health challenge, has plagued hundreds of millions of patients…
Introduction Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. In March 2024, the U.S. Food and Drug Administration (FDA) approved Duvyzat (givinostat), marking a significant advancement in…
Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease characterized by persistent eczematous eruptions and intense pruritus. During public awareness events, many patients report that visible skin lesions often lead to psychological distress, including…
On July 2, Betta Pharmaceuticals announced that its Class 1 innovative drug Terixilib Tartrate Capsules (brand name: Comenat®) has been officially approved by the National Medical Products Administration (NMPA). In combination with fulvestrant, the drug…
